Beta blockers tied to improved TNBC survival

Xray image of breast cancer

Author: Shreeya Nanda medwireNews: Among women with triple-negative breast cancer (TNBC), the use of beta blockers may improve BC-specific survival, suggests a population-based cohort study and meta-analysis. “The biological reason behind the association between β-blocker use and improved prognosis for TNBC patients but not for other BC patients remains unclear,” say the study authors in […]

Neutrophil to lymphocyte ratio may help identify ICI candidates in NSCLC

leukocyte attacking a cancer cell

Author: Laura Cowen medwireNews: A low baseline neutrophil to lymphocyte ratio (NLR) may identify patients with non-small-cell lung cancer (NSCLC) who are more likely to derive survival benefit from atezolizumab than from docetaxel, study findings indicate. Writing in Cancer, Alessio Cortellini (Imperial College London, UK) and co-authors say: “The NLR proved to be an effective tool […]

JAVELIN Bladder 100 exploratory analyses point to wide use of maintenance avelumab

Illustration of bladder cancer

Author: Shreeya Nanda medwireNews: Maintenance treatment with avelumab improves the long-term outcomes of advanced urothelial cancer patients regardless of their response to first-line chemotherapy and receipt of second-line therapy, suggest exploratory analyses of the JAVELIN Bladder 100 trial. The findings were presented in posters at the 2022 ASCO Annual Meeting in Chicago, Illinois, USA, and […]

PROpel: mCRPC patients benefit from add-on olaparib

prostate cancer cells dividing

Author: Shreeya Nanda medwireNews: Supplementing first-line abiraterone acetate with olaparib significantly improves the outcomes of patients with metastatic castration-resistant prostate cancer (mCRPC), show phase 3 data reported at the 2022 ASCO Genitourinary Cancers Symposium in San Francisco, California, USA. The presenting author – Fred Saad, from Centre Hospitalier de l’Université de Montréal in Quebec, Canada […]

Darolutamide add-on prolongs survival in mHSPC

prostate cancer cells

Author: Laura Cowen medwireNews: Adding the androgen receptor inhibitor darolutamide to androgen-deprivation therapy plus docetaxel significantly improves overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC), show data from the phase 3 ARASENS trial. Furthermore, the “survival benefit was observed despite a high percentage of patients who received subsequent life-prolonging systemic therapy in […]

ATLANTIS points to maintenance benefit of rucaparib in mUC

Simon Crabb outlines the final results of the rucaparib arm of the ATLANTIS trial of maintenance therapy in patients with metastatic urothelial cancer, and discusses them in light of the recent JAVELIN Bladder 100 and ATLAS trials (4:47). This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, […]